

With AMVUTTRA® (vutrisiran) for the treatment of the polyneuropathy
of hATTR amyloidosis in adults, your patients may1
FEEL MORE IN THE MOMENT1-3
AMVUTTRA may halt the progression of or reverse the polyneuropathy of hATTR amyloidosis with dosing 4 times per year1,3
AMVUTTRA may halt the progression of or reverse the polyneuropathy of hATTR amyloidosis with dosing 4 times per year1,3
AMVUTTRA may halt the progression of or reverse the polyneuropathy of hATTR amyloidosis with dosing 4 times per year1,3
At 9 months in a randomized, open-label study, patients treated with AMVUTTRA once every 3 months were compared with an external placebo group and demonstrated:
Improvement in neuropathy impairment, as measured by mNIS+71,3
Improvement in quality of life, as measured by Norfolk QoL-DN1,3
Improvement in gait speed, as measured by 10MWT1,3
10MWT=10-meter walk test; hATTR=hereditary transthyretin-mediated; mNIS+7=modified Neuropathy Impairment Score + 7; Norfolk QoL-DN=Norfolk Quality of Life-Diabetic Neuropathy.
Explore the pivotal study design and the efficacy and safety of AMVUTTRA
Learn how to administer AMVUTTRA
Find out how to get your patients started with AMVUTTRA